Preferred Name |
temsirolimus |
|
Synonyms |
rapamycin 42-(2,2-bis(hydroxymethyl)propionate) |
|
ID |
http://purl.bioontology.org/ontology/MESH/C401859 |
|
altLabel |
rapamycin 42-(2,2-bis(hydroxymethyl)propionate) CCI 779 rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) Torisel CCI-779 |
|
cui |
C0796512 C1951646 C1707080 |
|
Has mapping qualifier | ||
HM |
D020123/Q000031 |
|
II |
D047428 D000970 |
|
Inverse of RB |
624KN6GM2T 0 |
|
isa | ||
LT |
TRD |
|
Mapped to | ||
MDA |
19991217 |
|
MeSH Frequency |
884 |
|
MMR |
20210701 |
|
notation |
C401859 |
|
PA |
D000091203 |
|
prefLabel |
temsirolimus |
|
SC |
1 |
|
Scope Statement |
structure in first source; inhibits mTOR protein |
|
SRC |
Bull Cancer 1999 Oct;86(10):808-11 |
|
TERMUI |
T000913136 T707936 T403101 T403100 T675184 |
|
TH |
NLM (1999) FDA SRS (2017) USAN (19XX) INN (19XX) NLM (2006) FDA SRS (2015) NLM (2017) NLM (2007) |
|
tui |
T109 T121 |
Create mapping